stockrow
Saturday 7 November 2026
Export RIGL’s income statement to Excel — free account
Rigel Pharmaceuticals, Inc.
RIGL Healthcare Biotechnology
Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024.
- Revenue
- +16.5%
- EPS
- −54.8%
- Free cash flow
- +43.9%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
39.59
6.12
−13.39%
Follow RIGL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
185.94% | 174.08% | 126.90% | 109.18% | |
Piotroski F-Score |
6 | 6 | 4 | 5 | |
| 108.34% | 107.04% | 88.46% | 80.16% | ||
ROIC |
30.28% | 29.03% | 16.48% | 13.69% | |
Return on Tangible Assets |
260.43% | 252.00% | 357.90% | 279.89% | |
Average Days of Receivables |
64.20 | 60.81 | 73.90 | 71.50 | |
Free Cash Flow per Share |
4.21 | 4.31 | 0.48 | 4.81 | |
Free Cash Flow |
75.66 | 79.27 | 8.82 | 89.92 | |
Capital Expenditures |
— | — | (70.57) | — | |
| Other line items | |||||
Cash ROIC |
13.30% | 14.12% | 1.69% | 16.52% | |
Accounts Receivable Turnover |
6.30 | 6.55 | 5.77 | 5.63 | |
Accounts Payable Turnover |
3.73 | 4.70 | 4.22 | 3.91 | |
Inventory Turnover |
2.24 | 2.43 | 1.92 | 2.05 | |
Average Days of Payables |
133.77 | 82.62 | 61.41 | 139.82 | |
Days of Inventory on Hand |
214.04 | 214.60 | 219.97 | 193.14 | |
Tax Rate |
2.01 | 1.99 | 2.76 | 3.08 | |
Research and Development Expense of Revenue |
11.31% | 12.19% | 15.78% | 18.94% | |
Selling, General and Administrative Expense of Revenue |
39.38% | 39.64% | 44.16% | 44.42% | |
Share Based Compensation of Revenue |
4.32% | 4.28% | 5.93% | 6.21% | |
Interest Coverage |
17.14 | 18.05 | 15.00 | 18.17 | |
Operating CF/Net income |
0.21 | 0.22 | 0.25 | 0.29 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | (40.70) | 0.00 | |
Revenue per Share |
16.36 | 16.28 | 14.93 | 15.40 | |
Operating CF per Share |
4.21 | 4.31 | 4.28 | 4.81 | |
Capex per Share |
0.00 | 0.00 | (3.81) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.26 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026